**Planning Committee for Gene Drive Regulations in US**

**5-6 AM AU Eastern Std. Time (AEST), June 10, 2017**

**Attendees**: Fred Gould, Stas Burgiel, John Eisemann, Royden Saah (scribe)

**Regrets**: JP Chretien, Jamie Reaser, Gregg Howald

**Agenda and Notes**

**Key Meeting Objectives**

* Bring developers of gene drive tech and US regulators to assist in Coordinated Framework update
* Use case studies to identify where products should land and how they will be handled within the regulatory system.
* Question – will this be focused exclusively on GBIRd – A: Not necessarily, only if it would benefit.
	+ Consensus gained to have the meeting focused on gene drives (vertebrate or mammalian only?)
* To be further determined by potential funders of this meeting
	+ Comment: NISC (National Invasive Species Council) and STPI (Science & Technology Policy Institute) are working hand in hand on this
	+ Action Item #1: Stas will coordinate will connect with STPI to get an interim mtg with Royden on these items. Will keep JP and Jamie informed

**Outputs for Meeting**

* To be further determined by potential funders of this meeting – see Action Item #1

**Length of meeting**

* Decision is for two days. See detail below.
* Various configurations discussed. Group settled on a two day meeting. Day 1 is all inclusive (geneticists, regulators, safety experts, etc.) focused on case studies and current information. The first have of Day 2 will continue from Day 1. The second half will be closed to non-gov’t entities, exclusively for US Gov’t regulators and policy experts.

**Date for meeting**

* Dates discussed. Must be within Oct and Nov.
* Request that this meeting be timed with Annual GBIRd Meeting
* Discussion around FNIH meeting on communication and marketing of synthetic biology planned for Nov 4th.
* Suggestion made for GBIRd meeting to occur Sunday Nov 5th **and the regulatory meeting for Nov 6-7th.**
	+ Action Item #2: Stas will check in JP and Jamie and assess for dates.
	+ Action Item #3: Royden will check in with Brinda Dass regarding any activity/meetings involving regulators that could affect this date.
* Time for next planning committee meeting – group decided 3 weeks. Action Item #4: Royden to set up calendar date for this meeting.

**Composition of Planning Committee**

* UPDATE: Royden had previously suggested Brinda Dass for the Planning Committee
	+ Brinda is leaving FDA. She has offered to be on the planning committee.
		- There are pros and cons regarding this.
* Another suggestion was to invite Laura Eppstein on the committee.
	+ Action Item #5: Stas will bring these possibilities up to JP & Jamie regarding Laura vs Brinda vs FDA staff on the Coordinated Framework Working Group
* Representation on Planning Committee from OSTP/STPI
	+ Action Item #6: Stas will discuss having a back up from STPI or OSTP if/when JP is not able to make the planning committee meetings.

NOTE: Action Items # 1, 2, 5, & 6 can be covered in one or two conversations ☺